Merck KGaA (1MRK) Stock Price & Analysis
1MRK Stock Chart & Stats
- Day’s Range
- EUR 150.60 - EUR 151.70
- 52-Week Range
- EUR 102.35 - EUR 192.00
- Previous Close
- EUR 150.65
- Volume
- N/A
- Average Volume (3M)
- 89
- Market Cap
- EUR 65.78B
- Enterprise Value
- EUR 74.31B
- Total Cash (Recent Filing)
- EUR 1.96B
- Total Debt (Recent Filing)
- EUR 12.30B
- Price to Earnings (P/E)
- 27.8
- Beta
- 0.65
- Next Earnings
- Nov 12, 2026 (Est.)
- EPS Estimate
- 2.18
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 1.45%
Bulls Say, Bears Say
Bulls Say
Manageable Leverage
Manageable leverage and a larger equity base provide financial resilience across Merck KGaA’s three sectors. This supports continued investment in medicines, research tools and electronic materials while reducing the balance-sheet strain that can restrict strategic flexibility.
Healthy Margins
Healthy gross and operating margins indicate that Merck KGaA retains meaningful profitability across its diversified portfolio. A solid margin structure can help fund innovation, commercial execution and product development even when revenue growth is uneven.
Positive Free Cash Flow
Meaningfully positive and improving trailing free cash flow strengthens Merck KGaA’s ability to support internal investment, maintain financial flexibility and pursue its long-term strategy. Cash generation provides a durable foundation despite variability between individual years.
Bears Say
Uneven Revenue Growth
Revenue stagnation across 2023–2025 shows that the company’s diversified businesses have not delivered consistently expanding demand. A single TTM rebound is encouraging, but uneven growth can make operating leverage, planning and sustained earnings expansion less dependable.
Earnings Pressure
Net income remaining below recent annual peaks indicates that strong gross and operating margins have not translated into comparable bottom-line performance. Persistent earnings pressure could limit reinvestment capacity and weaken the pace of shareholder returns over coming quarters.
Moderate Cash Conversion
Moderate and volatile cash conversion means accounting profits have not consistently become equivalent levels of available cash. This can constrain flexibility for acquisitions, innovation and capital returns, particularly if weaker conversion persists alongside uneven revenue and earnings.
Merck KGaA News
1MRK FAQ
What was Merck KGaA’s price range in the past 12 months?
What is Merck KGaA’s market cap?
When is Merck KGaA’s upcoming earnings report date?
How were Merck KGaA’s earnings last quarter?
Is Merck KGaA overvalued?
Does Merck KGaA pay dividends?
What is Merck KGaA’s EPS estimate?
How many shares outstanding does Merck KGaA have?
What happened to Merck KGaA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Merck KGaA?
What is the TipRanks Smart Score and how is it calculated?
Merck KGaA Stock Smart Score
Company Description
Merck KGaA
Merck KGaA is a German science and technology company with operations divided into three core segments: Life Science, Healthcare, and Electronics. The Life Science division supplies essential tools, chemicals, and equipment to academic research institutions, biotechnology firms, pharmaceutical manufacturers, and various industrial sectors. It also offers specialized process development expertise, such as continuous bioprocessing for drug manufacturers, provides a range of testing kits, reagents, and services, and develops solutions for analyzing environmental samples like air, water, and soil. Furthermore, this segment aids in assessing nutritional value and identifying quality control issues. In its Healthcare segment, the company is involved in the entire lifecycle of prescription drugs and biopharmaceuticals, from initial discovery and development through manufacturing and marketing. Its therapeutic focus areas include oncology, neurology and immunology, fertility, endocrinology, cardiovascular diseases, diabetes, thyroid disorders, and multiple sclerosis. This segment also produces general medicines, injection devices, and software for disease monitoring. The Electronics division delivers critical materials for the semiconductor and display industries. It also specializes in surface design, providing delivery systems and services, along with a variety of surface solutions for applications such as cosmetics, effect pigments, and other functional materials. Merck KGaA is also actively engaged in strategic partnerships. These include in-licensing agreements with Debiopharm International SA for developing treatments for head and neck cancer, with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for metastatic colorectal cancer drug candidates, and with Abbisko Therapeutics Co. Ltd. for therapies targeting tenosynovial giant cell tumors. Additionally, the company is involved in collaborations focused on discovering and developing targeted protein degraders against critical oncogenic proteins. Founded in 1668 and headquartered in Darmstadt, Germany, Merck KGaA operates as a subsidiary of E. Merck KG.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Kai Beckmann
- Employees
- 62,136
- Website
- www.merckgroup.com
- Address
- Frankfurter Strasse 250, Darmstadt, HE, 64293, DE
Merck KGaA (1MRK) Earnings & Revenues
1MRK Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 4 | 3 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 12 | 0 | 0 |
